The radiosensitising effect of the PARP inhibitor olaparib on tumours has been reported in pre-clinical lung cancer models.11,29,30 However, the effect of olaparib and thoracic radiation on normal tissue toxicity has rarely been assessed in vivo. This evidence concerns the gene PARP1 and lung carcinoma.